Valuation: Exagen Inc.

Market Cap 21Cr 19Cr 17Cr 16Cr 29Cr 1.98TCr 30Cr 204.43Cr 82Cr 1.04TCr 78Cr 76Cr 3.28TCr P/E 2026 *
-13x
P/E 2027 * -16.7x
Enterprise Value 21Cr 19Cr 17Cr 16Cr 29Cr 1.98TCr 30Cr 204.43Cr 82Cr 1.04TCr 78Cr 76Cr 3.28TCr EV / Sales 2026 *
2.82x
EV / Sales 2027 * 2.55x
Free-Float
61.54%
Yield 2026 *
-
Yield 2027 * -
1 day-1.26%
1 week+18.16%
Current month+5.66%
1 month+5.66%
3 months+83.94%
6 months+196.21%
Current year+41.28%
1 week 7.05
Extreme 7.05
8.88
1 month 7.05
Extreme 7.05
9.22
Current year 2.59
Extreme 2.59
9.22
1 year 2.59
Extreme 2.59
11.92
3 years 1.3
Extreme 1.3003
12.23
5 years 1.3
Extreme 1.3003
14.85
10 years 1.3
Extreme 1.3003
29.86
Manager TitleAgeSince
Chief Executive Officer 41 17/10/2022
Director of Finance/CFO 57 01/09/2024
Chief Tech/Sci/R&D Officer - 23/06/2025
Director TitleAgeSince
Chairman 73 19/01/2023
Director/Board Member 63 30/07/2019
Director/Board Member 56 17/06/2021
Date Insider Type Main position Quantity % Market Cap. Importance
01/09/26 Sell

Chief Financial Officer

-22,185 0.0916%
12/03/26 Free

Chief Financial Officer

1,26,511 0.5582%
12/03/26 Free

Chief Executive Officer

2,50,000 1.1031%
Change 5-day change 1-year change 3-year change Capi.($)
-1.26%+18.16%-26.96%+432.88% 21Cr
-0.09%-3.44%+17.68%+32.70% 12TCr
-1.02%+0.89%+1.37%+111.87% 9.88TCr
-4.98%+2.56%+114.42%+1,003.33% 5.97TCr
-1.84%+9.86%+43.22%+82.37% 2.93TCr
+1.44%+1.95%-6.67%+93.57% 3.01TCr
-0.43%+4.11%+43.28%+94.59% 2.77TCr
+0.99%+1.79%+30.98%+413.15% 2.2TCr
-0.72%+5.53%-18.63%-12.38% 2.07TCr
0.00%-0.63%-4.27%+31.71% 1.71TCr
Average -0.79%+4.08%+19.44%+228.38% 4.21TCr
Weighted average by Cap. -1.01%+1.07%+27.30%+218.65%

Financials

2026 *2027 *
Net sales 7.39Cr 6.62Cr 6.09Cr 5.52Cr 10Cr 701.82Cr 11Cr 73Cr 29Cr 369.18Cr 28Cr 27Cr 1.16TCr 8.15Cr 7.3Cr 6.72Cr 6.08Cr 11Cr 773.98Cr 12Cr 80Cr 32Cr 407.14Cr 31Cr 30Cr 1.28TCr
Net income -1.59Cr -1.43Cr -1.31Cr -1.19Cr -2.22Cr -151.29Cr -2.26Cr -16Cr -6.28Cr -80Cr -5.98Cr -5.85Cr -250.97Cr -1.34Cr -1.2Cr -1.1Cr -99.87L -1.87Cr -127.04Cr -1.9Cr -13Cr -5.28Cr -67Cr -5.02Cr -4.91Cr -210.75Cr
Net Debt - -
Projected Income Statement - Annual - Exagen Inc.
Logo Exagen Inc.
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related disease including, among others, systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Employees
218
Date Price Change Volume
30/26/30 $8.590 -1.26% 3,94,013
29/26/29 $8.700 +3.57% 3,78,377
28/26/28 $8.400 +7.97% 3,48,824
27/26/27 $7.780 +4.15% 1,80,709
26/26/26 $7.470 +2.75% 1,91,379
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Exagen Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.590USD
Average target price
10.57USD
Spread / Average Target
+23.07%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Exagen Inc.